The Yangtze River Delta Sub-Center for Drug and Device Review and Inspection of the State Drug Administration was officially listed today

Today (December 22), the State Drug Administration Drug Review and Inspection Yangtze River Delta Sub-Center, medical device technical review and inspection Yangtze River Delta Sub-Center officially listed.
Previously, after full consultation with the Shanghai Municipal Government, the State Drug Administration and the Shanghai Municipal Government decided to set up the Yangtze River Delta Sub-Center for Drug Review and Inspection of the State Drug Administration and the Yangtze River Delta Sub-Center for Technical Review and Inspection of Medical Devices in Shanghai. The practical platform for promoting the integrated development of high quality in the Yangtze River Delta region, the cooperation platform for deepening the reform of the drug medical device review and approval system, and the incubation platform for serving the innovation and development of the pharmaceutical industry aim to further deepen the reform of the review and approval system, promote the transformation of the achievements of pharmaceutical medical devices in the Yangtze River Delta, industrial aggregation and innovation development, and promote the Yangtze River Delta to become the most dynamic innovation highland of pharmaceutical medical devices in the world, so as to better meet the people's new expectations for drug safety and innovative research and development.
For the specific functions of the two sub-centers, at the 22nd Shanghai International Symposium on Biotechnology and Medicine held in September this year, the founding head of Shanghai Branch said: "After the establishment of the two centers, some drug and device reviews can be reviewed in Shanghai, so that the Yangtze River Delta region of biopharmaceutical enterprises new drug approval and speed up."
data review, on-site review and a large number of pre-acceptance communication and other drug review matters in the near solution, will hopefully shorten the development cycle of new drugs, reduce research and development costs, accelerate the Yangtze River Delta biopharmaceutical industry innovation pace.
" According to the information obtained by Medical Valley, the State Drug Administration Drug Review and Inspection Yangtze River Delta Sub-Center, medical device technical review and inspection Yangtze River Delta Sub-Center office address will be located in Zhangjiang Science City.
。